AI-Driven Risk Intelligence. Proteome-Level Precision. Clinical-Grade Execution.
Cardiovascular disease remains the leading cause of death worldwide, often progressing silently for years before acute events such as myocardial infarction or stroke occur. Traditional risk models—while clinically useful—rely largely on demographic variables and limited laboratory parameters, frequently underestimating an individual’s true biological risk.
Through our collaboration with Prevencio, a pioneer in AI-driven multi-protein cardiovascular diagnostics, we provide next-generation blood-based cardiovascular risk assessment. Prevencio’s HART® platform integrates validated multi-analyte protein signatures with advanced machine-learning algorithms to:
- Quantify near-term risk of major adverse cardiovascular events (MACE)
- Detect obstructive coronary artery disease (CAD) through non-invasive molecular testing
- Improve clinical decision-making beyond traditional lipid-centric risk models
The HART platform is clinically implemented through validated laboratory assays, including:
- HART CADhs™ — CPT Code: 0308U
- HART CVE™ — CPT Code: 0309U
These tests enable physicians to incorporate multi-protein cardiovascular risk intelligence directly into clinical decision workflows, and this approach transforms cardiovascular screening from population-based probability estimation to biology-driven precision risk stratification.
In addition, the HART PAD™ panel enables blood-based assessment of obstructive peripheral artery disease (PAD) and can be used to monitor pre- and post-treatment therapeutic effects. In clinical validation studies, the platform demonstrated significantly higher diagnostic accuracy(AUC ≈ 0.85) compared with standard-of-care cardiac stress testing (AUC ≈ 0.52) for identifying coronary artery disease.
Together, these technologies represent a major step toward scalable molecular cardiology, enabling earlier detection, improved risk stratification, and more personalized cardiovascular management through simple blood testing.
Complete360® Molecular Depth & Longitudinal Monitoring
At Complete Omics, cardiovascular biomarker panels are deployed within the Complete360® infrastructure — our ultra-deep, quantitatively harmonized proteomic platform designed for clinical reproducibility.
Complete360® enables:
- High-precision quantification of multi-protein cardiovascular signatures
- Integration of expanded proteomic markers beyond conventional panels
- Longitudinal molecular trajectory tracking for dynamic risk monitoring
- Standardized workflows engineered for clinical-grade consistency
By combining AI-validated cardiovascular algorithms with proteome-level analytical depth, we elevate cardiovascular testing from static risk categorization to continuous molecular surveillance.
CLIA-Certified. CAP-Accredited. Built for Clinical Deployment.
All cardiovascular testing is performed within our CLIA-Certified, CAP-Accredited clinical laboratory, ensuring the highest standards of regulatory compliance, analytical accuracy, and quality control.
Our infrastructure is designed not only for innovation, but for scalable clinical implementation — enabling:
- CPT-coded, insurance-reimbursable testing pathways
- Regulatory-aligned laboratory processes
- Reliable deployment across preventive, primary care, and specialty cardiology settings
By integrating Prevencio’s AI cardiovascular intelligence with the execution discipline of Complete360® under stringent CLIA and CAP oversight, we are advancing a new standard in cardiovascular screening — proactive, quantitative, and molecularly precise.